Global Benign Prostatic Hyperplasia (BPH) Treatment Market Growth (Status and Outlook) 2023-2029

Global Benign Prostatic Hyperplasia (BPH) Treatment Market Growth (Status and Outlook) 2023-2029

Benign prostatic hyperplasia (BPH), also called prostate enlargement, is a noncancerous increase in size of the prostate. Symptoms may include frequent urination, trouble starting to urinate, weak stream, inability to urinate, or loss of bladder control. Complications can include urinary tract infections, bladder stones, and chronic kidney problems.

LPI (LP Information)' newest research report, the “Benign Prostatic Hyperplasia (BPH) Treatment Industry Forecast” looks at past sales and reviews total world Benign Prostatic Hyperplasia (BPH) Treatment sales in 2022, providing a comprehensive analysis by region and market sector of projected Benign Prostatic Hyperplasia (BPH) Treatment sales for 2023 through 2029. With Benign Prostatic Hyperplasia (BPH) Treatment sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world Benign Prostatic Hyperplasia (BPH) Treatment industry.

This Insight Report provides a comprehensive analysis of the global Benign Prostatic Hyperplasia (BPH) Treatment landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyzes the strategies of leading global companies with a focus on Benign Prostatic Hyperplasia (BPH) Treatment portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms’ unique position in an accelerating global Benign Prostatic Hyperplasia (BPH) Treatment market.

This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Benign Prostatic Hyperplasia (BPH) Treatment and breaks down the forecast by type, by application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Benign Prostatic Hyperplasia (BPH) Treatment.

The global Benign Prostatic Hyperplasia (BPH) Treatment market size is projected to grow from US$ million in 2022 to US$ million in 2029; it is expected to grow at a CAGR of % from 2023 to 2029.

United States market for Benign Prostatic Hyperplasia (BPH) Treatment is estimated to increase from US$ million in 2022 to US$ million by 2029, at a CAGR of % from 2023 through 2029.

China market for Benign Prostatic Hyperplasia (BPH) Treatment is estimated to increase from US$ million in 2022 to US$ million by 2029, at a CAGR of % from 2023 through 2029.

Europe market for Benign Prostatic Hyperplasia (BPH) Treatment is estimated to increase from US$ million in 2022 to US$ million by 2029, at a CAGR of % from 2023 through 2029.

Global key Benign Prostatic Hyperplasia (BPH) Treatment players cover Pfizer, Sanofi, GlaxoSmithKline, Boston Scientific, Teleflex, Cardinal Health, Allergan, Teva Pharmaceutical and Mylan, etc. In terms of revenue, the global two largest companies occupied for a share nearly % in 2022.

This report presents a comprehensive overview, market shares, and growth opportunities of Benign Prostatic Hyperplasia (BPH) Treatment market by product type, application, key players and key regions and countries.

Market Segmentation:

Segmentation by type
Drugs
Devices

Segmentation by application
Hospitals
Clinics
Others

This report also splits the market by region:
Americas
United States
Canada
Mexico
Brazil
APAC
China
Japan
Korea
Southeast Asia
India
Australia
Europe
Germany
France
UK
Italy
Russia
Middle East & Africa
Egypt
South Africa
Israel
Turkey
GCC Countries

The below companies that are profiled have been selected based on inputs gathered from primary experts and analyzing the company's coverage, product portfolio, its market penetration.
Pfizer
Sanofi
GlaxoSmithKline
Boston Scientific
Teleflex
Cardinal Health
Allergan
Teva Pharmaceutical
Mylan
Eli Lilly

Please note: The report will take approximately 2 business days to prepare and deliver.